Loading...
•
Jun 30, 2020
Enanta Pharmaceuticals Q3 2020 Earnings Report
Enanta Pharmaceuticals reported financial results for the third quarter of fiscal year 2020.
Key Takeaways
Enanta Pharmaceuticals reported a total revenue of $18.7 million, consisting of royalty revenue, for the three months ended June 30, 2020. The net loss for the quarter was $14.3 million, or a loss of $0.71 per diluted common share. The company's cash, cash equivalents, and marketable securities totaled $435.4 million at the end of the quarter.
Initiated Phase 1b Study of EDP-514 in Viremic HBV Patients and Resumed Phase 1b Study of EDP-514 in NUC-Suppressed HBV Patients
Plans to Initiate Two Phase 2 Studies of EDP-938 in Pediatric and Adult Transplant Patients with RSV in 4Q 2020
Initiated ARGON-2 Phase 2b Study of EDP-305 in Patients with NASH, On Track to Initiate Phase 1 Study of EDP-297 for NASH in 3Q 2020
Royalty Revenue for the Quarter was $18.7 Million
Enanta Pharmaceuticals
Enanta Pharmaceuticals
Enanta Pharmaceuticals Revenue by Segment
Revenue by Segment
Royalty Revenue
CapyFin.com Forward Guidance
Enanta plans to issue its fiscal fourth quarter financial results press release, and hold a conference call regarding those results, on November 23, 2020.